Switch theme
Sign up to access all valuation multiples
Establishment Labs Holdings Inc is a medical technology company engaged in offering medical devices and aesthetic products. It is involved in the designing, manufacturing, and marketing of silicone-filled breast and body-shaping implants. The company markets its products under Motiva implants Brand. It distributes its products to medical distributors; and physicians, hospitals, and clinics in the form of direct sales. Its geographical segments are Europe, Latin America, Asia-Pacific/Middle East, and Others.
2004
1.0K+
LTM Revenue $183M
LTM EBITDA -$23.6M
$1.2B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Establishment Labs has a last 12-month revenue (LTM) of $183M and a last 12-month EBITDA of -$23.6M.
In the most recent fiscal year, Establishment Labs achieved revenue of $166M and an EBITDA of -$56.2M.
Establishment Labs expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Establishment Labs valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $183M | XXX | $166M | XXX | XXX | XXX |
| Gross Profit | $123M | XXX | $110M | XXX | XXX | XXX |
| Gross Margin | 67% | XXX | 66% | XXX | XXX | XXX |
| EBITDA | -$23.6M | XXX | -$56.2M | XXX | XXX | XXX |
| EBITDA Margin | -13% | XXX | -34% | XXX | XXX | XXX |
| EBIT | -$45.9M | XXX | -$50.0M | XXX | XXX | XXX |
| EBIT Margin | -25% | XXX | -30% | XXX | XXX | XXX |
| Net Profit | -$74.5M | XXX | -$84.6M | XXX | XXX | XXX |
| Net Margin | -41% | XXX | -51% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $129M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Establishment Labs's stock price is $34.
Establishment Labs has current market cap of $995M, and EV of $1.2B.
See Establishment Labs trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.2B | $995M | XXX | XXX | XXX | XXX | $-2.60 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Establishment Labs has market cap of $995M and EV of $1.2B.
Establishment Labs's trades at 6.9x EV/Revenue multiple, and -20.5x EV/EBITDA.
Equity research analysts estimate Establishment Labs's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Establishment Labs has a P/E ratio of -13.4x.
See valuation multiples for Establishment Labs and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $995M | XXX | $995M | XXX | XXX | XXX |
| EV (current) | $1.2B | XXX | $1.2B | XXX | XXX | XXX |
| EV/Revenue | 6.3x | XXX | 6.9x | XXX | XXX | XXX |
| EV/EBITDA | -48.8x | XXX | -20.5x | XXX | XXX | XXX |
| EV/EBIT | -25.1x | XXX | -23.0x | XXX | XXX | XXX |
| EV/Gross Profit | 9.4x | XXX | n/a | XXX | XXX | XXX |
| P/E | -13.4x | XXX | -11.8x | XXX | XXX | XXX |
| EV/FCF | -22.4x | XXX | -15.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialEstablishment Labs's last 12 month revenue growth is 25%
Establishment Labs's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.2M for the same period.
Establishment Labs's rule of 40 is -10% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Establishment Labs's rule of X is 51% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Establishment Labs and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 25% | XXX | 25% | XXX | XXX | XXX |
| EBITDA Margin | -13% | XXX | -34% | XXX | XXX | XXX |
| EBITDA Growth | -74% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -10% | XXX | -8% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 51% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 12% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 96% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Establishment Labs acquired XXX companies to date.
Last acquisition by Establishment Labs was XXXXXXXX, XXXXX XXXXX XXXXXX . Establishment Labs acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Establishment Labs founded? | Establishment Labs was founded in 2004. |
| Where is Establishment Labs headquartered? | Establishment Labs is headquartered in United States of America. |
| How many employees does Establishment Labs have? | As of today, Establishment Labs has 1.0K+ employees. |
| Who is the CEO of Establishment Labs? | Establishment Labs's CEO is Mr. Fillipo Caldini. |
| Is Establishment Labs publicy listed? | Yes, Establishment Labs is a public company listed on NAS. |
| What is the stock symbol of Establishment Labs? | Establishment Labs trades under ESTA ticker. |
| When did Establishment Labs go public? | Establishment Labs went public in 2018. |
| Who are competitors of Establishment Labs? | Similar companies to Establishment Labs include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Establishment Labs? | Establishment Labs's current market cap is $995M |
| What is the current revenue of Establishment Labs? | Establishment Labs's last 12 months revenue is $183M. |
| What is the current revenue growth of Establishment Labs? | Establishment Labs revenue growth (NTM/LTM) is 25%. |
| What is the current EV/Revenue multiple of Establishment Labs? | Current revenue multiple of Establishment Labs is 6.3x. |
| Is Establishment Labs profitable? | Yes, Establishment Labs is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Establishment Labs? | Establishment Labs's last 12 months EBITDA is -$23.6M. |
| What is Establishment Labs's EBITDA margin? | Establishment Labs's last 12 months EBITDA margin is -13%. |
| What is the current EV/EBITDA multiple of Establishment Labs? | Current EBITDA multiple of Establishment Labs is -48.8x. |
| What is the current FCF of Establishment Labs? | Establishment Labs's last 12 months FCF is -$51.3M. |
| What is Establishment Labs's FCF margin? | Establishment Labs's last 12 months FCF margin is -28%. |
| What is the current EV/FCF multiple of Establishment Labs? | Current FCF multiple of Establishment Labs is -22.4x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
